您好!欢迎访问天济医药官方网站。
服务热线:010-85518700     加入收藏 | 关于天济
关于天济所在位置:首页 > 公司简介 > 关于天济

关于天济

 北京文丰天济医药科技有限公司是由海归博士和资深投资团队共同创办的新药研发公司。公司致力于研发治疗自身免疫性及相关领域重大疾病的创新药物。

     公司架构完备,覆盖了新药研发、制造及营销的整个流程;具有“一条龙”式的产业转化和市场运营能力;在北京设有研发中心,在广东设有GMP生产基地和营销中心。 

公司现阶段主要产品为拥有完整自主知识产权、治疗银屑病的创新药本维莫德(Benvitimod;曾用名:苯烯莫德;商品名:欣比克)。本维莫德是首创新一代治疗炎症性和自身免疫性疾病的非激素类新型小分子化学药,是治疗性芳香烃受体调节剂(TAMA : Therapeutic Aryl hydrocarbon receptor Modulating Agent),已于2019年在中国获得国家1类新药证书是国家科技部“十一五”、“十二五”、“十三五” “重大新药创制”国家科技重大专项成果。 

Beijing Wenfeng Tianjipharma Ltd.(BWTL) is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative drugs for the treatment of inflammatory and auto-immune diseases. With its first antipsoriatic product, Benvitimod, on the market in China, BWTL is advancing a pipeline consisting of novel small molecules for several hard-to-treat, auto-immune diseases and dermatological disorders.

Benvitimod, a novel, non-steroid small molecule, has anti-inflammatory and immune-modulating activities related to cytokines that are involved in Th1 and Th17 type autoimmune inflammatory and in Th2 type allergic diseases. Benvitimod, with its positive clinical results in a Phase 3 trial in patients with eczema, would be the first approved NSAID topical therapy that could treat both psoriasis and eczema.